Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.
This study examined Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial. Findings provide evidence relevant to clinical and research application in this area.
This study examined Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial. Findings provide evidence relevant to clinical and research application in this area.
What the study was
- Study design
- Phase 2 clinical trial
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Nature medicine
Why it surfaced
Low-signal Hematologic malignancies entry (Phase 2 clinical trial design); retained for topic coverage completeness.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.